Altimmune (ALT) Restructuring Costs (2015)

Altimmune's (ALT) quarterly Restructuring Costs came in at $26886.0 in Q4 2015, down 93.64% on a QoQ basis from $422482.0 in Q3 2015.

Altimmune (ALT) Restructuring Costs (2015) Analysis & Trends

Altimmune (ALT) has 1 years of Restructuring Costs data on file, last reported at $26886.0 in Q4 2015.

  • On a quarterly basis, Restructuring Costs changed N/A year-over-year to $26886.0 in Q4 2015; TTM through Sep 2016 was $26886.0, a N/A change from a year earlier, with the FY2015 full-year figure at $2.5 million, changed N/A from the prior year.
  • Restructuring Costs for Q4 2015 stood at $26886.0, down from $422482.0 in the prior quarter.
  • Over the last five years, Restructuring Costs for ALT reached as high as $2.1 million in Q1 2015 and fell as low as $26886.0 in Q4 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Altimmune 7.96 Mn 7.96 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2015 26,886.00
Sep 30, 2015 422,482.00
Jun 30, 2015 35,982.00
Mar 31, 2015 2.06 Mn